XML 57 R8.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statement of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Operating activities      
Net loss $ (61,680) $ (85,779) $ (59,504)
Adjustments to reconcile net loss to net cash provided by / (used in) operating activities:      
Depreciation 6,040 5,679 4,470
Amortization of premium on investments 2,729 2,997 658
Loss on disposal of property and equipment 0 98 (10)
Stock-based compensation 32,132 27,681 18,698
Tax benefit on unrealized gain on available-for-sale securities (211) 0 0
Realized gain on sales of available-for-sale securities (37) (203) 0
Changes in operating assets and liabilities:      
Accounts receivable ($353, $578 and $979 from related party) 4,957 (1,952) 4,041
Prepaid expenses and other current assets 1,099 978 (1,628)
Other assets (136) (420) (795)
Accounts payable (298) 1,970 3,485
Accrued liabilities ($(430), $(2,549) and $1,828 from related party) 2,965 (2,126) 18,878
Deferred revenue 16,837 27,654 33,557
Lease financing liability 814 627 814
Other long-term liabilities 1,897 4,225 (250)
Net cash provided by (used in) operating activities 7,108 (18,571) 22,414
Investing activities      
Purchases of property and equipment (1,252) (1,977) (8,118)
Proceeds from sale of property and equipment 0 2 10
Purchases of available-for-sale securities (9,041) (41,736) (144,727)
Proceeds from sales of available-for-sale securities 4,298 15,342 0
Proceeds from maturities of available-for-sale securities 12,617 22,501 45,546
Net cash provided by (used in) investing activities 6,622 (5,868) (107,289)
Financing activities      
Repayments of lease liability (403) (403) (403)
Proceeds from initial public offering, net of underwriting discounts and commission costs 0 0 155,933
Proceeds from AstraZeneca private placement 0 0 20,000
Cash paid for payroll taxes on restricted stock unit releases (2,740) (2,243) 0
Proceeds from issuance of common stock 9,881 14,992 1,697
Payments of deferred offering costs 0 0 (3,135)
Net cash provided by financing activities 6,738 12,346 174,092
Effect of exchange rate change on cash and cash equivalents (10) (38) (94)
Net increase (decrease) in cash and cash equivalents 20,458 (12,131) 89,123
Total cash and cash equivalents at beginning of period 153,324 165,455 76,332
Total cash and cash equivalents at end of period 173,782 153,324 165,455
Supplemental cash flow information:      
Interest payments 295 335 377
Balance in accounts payable and accrued liabilities related to purchases of property and equipment 356 931 280
Deferred offering costs recorded in accounts payable and accrued liabilities $ 0 $ 0 $ 974